VHT240920C270000
- 18.14
- 0.000.00%
Vanguard Health Care ETF Newsroom
Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
What the Options Market Tells Us About UnitedHealth Group
A Closer Look at 8 Analyst Recommendations For Merck & Co
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group, Maintains $591 Price Target
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $885 Price Target
Eli Lilly Analyst Ratings
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Johnson & Johnson Analyst Ratings
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer